Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Receivables (2016 - 2025)

Historic Receivables for Akebia Therapeutics (AKBA) over the last 10 years, with Q3 2025 value amounting to $69.3 million.

  • Akebia Therapeutics' Receivables rose 10380.35% to $69.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $69.3 million, marking a year-over-year increase of 10380.35%. This contributed to the annual value of $36.4 million for FY2024, which is 1465.17% down from last year.
  • Akebia Therapeutics' Receivables amounted to $69.3 million in Q3 2025, which was up 10380.35% from $78.2 million recorded in Q2 2025.
  • Over the past 5 years, Akebia Therapeutics' Receivables peaked at $138.6 million during Q2 2022, and registered a low of $19.1 million during Q1 2023.
  • Over the past 5 years, Akebia Therapeutics' median Receivables value was $38.8 million (recorded in 2021), while the average stood at $50.8 million.
  • In the last 5 years, Akebia Therapeutics' Receivables skyrocketed by 178718.29% in 2021 and then plummeted by 8550.29% in 2023.
  • Over the past 5 years, Akebia Therapeutics' Receivables (Quarter) stood at $70.7 million in 2021, then plummeted by 40.31% to $42.2 million in 2022, then increased by 1.04% to $42.6 million in 2023, then fell by 14.65% to $36.4 million in 2024, then soared by 90.45% to $69.3 million in 2025.
  • Its Receivables was $69.3 million in Q3 2025, compared to $78.2 million in Q2 2025 and $63.1 million in Q1 2025.